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ABSTRACT 
The association between selective serotonin reuptake inhibitors (SSRis) and 
hyponatraemia has been well documented, the elderly appearing to be at greatest risk. An 
analysis of data of hyponatraemia in the elderly using SSRis from all published cases and 
from the Committee on Safety of Medicines found that the mean time to detection was 
about 3 weeks after commencing SSRis. A wide range of time to detection (1-253 days) 
and non-specific symptoms suggest hyponatraemia is detected by chance rather than 
being specifically looked for. This is probably a sporadic, idiosyncratic phenomenon that 
is not dose related as A VP function determined by serum and urine concentrations was 
found to be normal in six elderly patients using sertraline. In the elderly there are 
physiological changes, a high prevalence of medical illnesses and concomitant drug use 
which may precipitate hyponatraemia. Together with a risk of altered water regulation in 
psychiatric illness this may account for the particular susceptibility of this group to 
hyponatraemia whilst using SSRis. 
AIMS & HYPOTHESIS 
This dissertation will explore the physiology of Arginine V asopressin and how changes 
in this system along with other physiological changes in the elderly make the elderly 
susceptible to hyponatraemia. This problem will then be explored in the context of 
elderly people with depression using SSRis which are known to cause hyponatraemia. 
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In the first part of the research section the aims are to report the published cases of 
hyponatraemia occurring whilst using SSRis from the United Kingdom and specifically 
focus on cases in people 60 years and older. Secondly to re-analyse all case reports in the 
literature looking only at this population. The third aim was to investigate whether 
dysregulation of vasopressin function in the elderly using SSRis is a sporadic or usual 
phenomenon. 
The null hypothesis is that A VP function is not disturbed by SSRis. 
INTRODUCTION 
1.0 General 
The elderly are a unique group and require special consideration when managing their 
mental health. On a psychological level they are confronting issues surrounding their 
independence, physical health and mortality so added mental illness can be devastating 
and frequently results in loss of independence, deterioration in physical health and even 
death. Dementia and depression are two mental illnesses that occur more frequently in 
this population and require treatment with psychoactive drugs. Insomnia is also often 
treated with psychoactive drugs. Part of the normal aging process involves a loss of 
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physiological functional reserve. This means any minor disturbances by illness or drugs 
can alter physiological function significantly. The elderly are more likely to have 
degenerative illnesses, particularly of the cardiovascular system, and are more likely to be 
taking medication, both prescribed and over the counter preparations. Polypharmacy is 
common. 
It is thus important to establish what physiological changes may be precipitated by a 
certain mental illness and how this occurs. Models involving cortisol and depression are 
well evolved. Psychoactive drugs may also affect physiological function themselves. This 
is superimposed on the physiological changes that have occurred due to aging, any 
underlying medical condition or other medication. These factors may interact with each 
other or have individual effects. 
New psychoactive drugs are being developed and promise fewer side effects reducing the 
risk of adverse reactions in the elderly. However, the effects of these drugs on 
physiological function need to be researched as it may give greater understanding to the 
pathophysiology of the mental illness and the mechanism of action of the drug. This will 
also make it easier to administer .these drugs more safely because possible physiological 
complications can be screened for. 
Selective serotonin reuptake inhibitors (SSRis) were introduced as safe antidepressant 
alternatives to tricyclic antidepressants and monoamine oxidase inhibitors and they have 
-
proved to be thus making them suitable for use in the elderly. Hyponatraemia associated 
with SSRI use is a well documented adverse reaction and may result in serious morbidity 
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or mortality. Exploring the frequency, characteristics and mechanism of this 
hyponatraemia will identify the extent of the problem, which people are at risk and allow 
safer use of these drugs. It will also allow some unraveling of the complex physiological 
interactions that occur in the elderly. Finally it may shed some more light on 
physiological changes associated with depression, particularly changes in arginine 
vasopressin (AVP) function. 
1.1 Depression in the elderly 
Depression is a serious illness that is common in the elderly. Depressive symptoms occur 
in around 15% of people 65 years and older with 3-10% fulfilling criteria for major 
depressive disorder (Alexopoulos, 1996, Reynolds, 1996, Rothschild, 1996, Skerritt et 
al., 1997). In medically ill elderly patients the incidence of major depression has been 
reported as high as 31 % and 45% of hospitalised elderly (Newhouse, 1996). Suicide rates 
rise dramatically in old age. The 1986 USA reported suicide rates were 21.6 per 100 000 
for persons 65 years or older compared with 12.8 per 100 000 for the general population. 
For elderly white men this rate was 40-75 per 100 000 (Newhouse, 1996, Reynolds 
1996). Untreated depression in the elderly is associated with considerable morbidity and 
mortality and may increase healthcare costs. The 1991 National Institute of Health 
I 
consensus development panel identified five objectives of treatment of depression in the 
elderly. These were 1) to reduce depressive symptoms, 2) to improve quality oflife, 3) to 
1 
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reduce the risk of relapse and recurrence, 4) to improve medical health, 5) to reduce 
healthcare costs and mortality (Reynolds, 1996). 
The effective treatment of depression in the elderly is complicated by comorbid physical 
illnesses, compliance difficulties and age related changes in drug absorption, distribution 
and metabolism (Newhouse, 1996, Skerritt et al., 1997). Changes in body weight and 
ratio of adipose tissue to lean body mass affect drug distribution and reduced renal and 
hepatic function influence drug clearance and plasma levels. Erratic failure of different 
enzyme systems also helps explain individual variation in drug metabolism (Skerritt et 
al., 1997). The elderly are more sensitive to the adverse effects of pharmacotherapy for 
depression and they ar~ more likely to be on several other drugs increasing the risk of 
interactions (Rothschild, 1996). The adverse effects of drugs is one of the five most 
important quality of care problems in older people and adverse drug effects are most 
consistently linked to polypharmacy (Hanlon et al., 1997). In one report 3 5% of older 
ambulatory patients using 5 or more medications experienced an adverse drug reaction 
over a one-year period. Of these 10----11 % had to attend a hospital emergency room or 
receive inpatient treatment (Hanlon et al., 1997). Psychotropic drugs, including all 
antidepressants, are among the most common classes of drugs associated with adverse 
drug effects in the elderly. High rates of psychotropic drug use have been described in the 
elderly with falls, impaired cognition and impaired self-care abilities being adverse 
outcomes associated with these drugs. In a report on 10263 elderly patients the 
frequencey of falls was 120% greater in users of antidepressants than non users (Ehly et 
al., 1997). 
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2.0 Selective serotonin re-uptake inhibitors in the elderly. 
SSRis were a novel group of antidepressants introduced with fluoxetine in the 1970s. 
Several others have appeared on the market since and the commonly used ones are 
fluoxetine, paroxetine, fluvoxamine, citalopram and sertraline. (Grebb, 1995). The half 
lives of SSRis range from 2-3 days for fluoxetine and 7-15 days for its active metabolite, 
norfluoxetine, to about 7-33 hours for the rest (Grebb, 1995, Preskom, 1997, Skerritt et 
al., 1997). They are all well absorbed after oral ingestion. They undergo extensive 
oxidative metabolism mediated by different cytochrome P450 isoenzymes in the liver 
(Preskom, 1997). They all have specific activity inhibiting neuronal serotonin re-uptake 
without significant effects on norepinephrine or dopamine re-uptake (Grebb, 1995, 
Preskom 1997). They all have similar clinical efficacy in depression. Some of them have 
been shown to be effective in other conditions e.g. obsessive compulsive disorder, 
bulimia, anxiety, panic disorder (Grebb, 1995). 
SSRis have different side effect profiles to tricyclic, heterocyclic and monoamine oxidase 
inhibiting antidepressants because they have little effect at dopaminergic, a.1-adrenergic, 
histaminergic and cholinergic receptors (Newhouse, 1996). They therefore lack the 
significant anticholinergic, cardiovascular and sedative effects of tricyclic 
antidepressants. SSRis represent an important advance over tricyclic antidepressants with 
respect to cardiac effects. SSRis have a much smaller conduction effect in the heart and 
do not produce clinically significant ECG changes. They are safer in patients with pre-
existing cardiac disease and undetected cardiac disease. They are also relatively safe in 
, 
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overdose (Reynolds, 1996, Skerritt et al., 1997). SSRls do not interfere with cognitive 
function, which is commonly a problem with psychotropic medication in the elderly 
(Rothschild, 1996, Ehly et al., 1997, Skerritt et al., 1997). They are also less associated 
with falls than tricyclic antidepressants (Grebb, 1995). 
The most common adverse effects associated with SSRls are gastrointestinal disturbances 
especially nausea, headaches, insomnia, somnolence, agitation, sexual dysfunction and 
loss of weight (Reynolds, 1996, Rothschild, 1996, Skerritt et al., 1997). The frequency of 
adverse effects of SSRls are probably similar to tricyclic antidepressants, but these 
effects are less troublesome and are associated with reduced adverse effect burden. 
Patients on SSRls are less likely to stop their medication because of adverse drug effects 
that those on tricyclic antidepressants (Newhouse, 1996, Skerritt et al., 1997). 
Results of controlled studies suggest SSRls are efficacious in the treatment of depression 
in the elderly and although few trials have been done comparing tricyclic antidepressants 
and SSRis, those that have been done generally show equal efficacy (Newhouse, 1996, 
Rothschild, 1996, Skerritt et al., 1997). There have been reports suggesting fluoxetine has 
low efficacy in the elderly with unipolar depression and older cardiac patients with severe 
melancholic depression, but more information is needed to confirm such findings 
(Reynolds, 1996). The reports of SSR1s in the elderly are difficult to interpret because 
sample sizes tend to be small, definitions of elderly differ and attrition rates tend to be 
high (Skerritt et al., 1997) 
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2.1 Cytochrome P450 enzymes, SSRis and drug interactions. 
There are more than 30 related enzymes in the family of cytochrome P450 enzymes. 
They are largely located in the endoplasmic reticulwn of hepatocytes, but also occur in 
other sites e.g. intestinal mucosa. They are involved in oxidative metabolism of several 
endogenous substances e.g. prost.aglandins, fatty acids, steroids, and also a nwnber of 
drugs. The majority of antidepressants and antipsychotics are metabolised by, or inhibit 
to a varying degree, one or more cytochrome P450 isoenzymes (Nemerof et al. 1996). 
The SSRis in particular have been found to be potent inhibitors of several different 
isoenzymes thus affecting the metabolism of drugs that are substrates of these enzymes 
(Ereshefsky et al., 1996, Nemerof et al., 1996, Preskom, 1997, Taylor & Lader, 1996). 
The size of this effect is illustrated in reports of tricyclic antidepressants plasma 
concentrations over baseline ranging 58-150% when co-administered with 50mg 
sertraline and 110-375% when co-administered with 20mg fluoxetine (Nemerof et al., 
1996). A drug can inhibit the activity of an isoenzyme without itself being a substrate at 
that site, so knowledge of the metabolic pathway of an SSRI does not predict its potential 
for drug interaction. Fortunately most drugs have several potential metabolic pathways 
and if a particular enzyme is inhibited its metabolism will continue albeit less efficiently 
(Ereshefsky et al., 1996). 
The roles of five cytochrome P450 isoenzymes have been established with respect to 
SSRis and these are CYP 2D6, CYP 1A2, CYP 2C9, CYP 2C19, and CYP 3A3/4 
(Ereshefsky et al., 1996, Nemerof et al., 1996, Preskom, 1997, Taylor & Lader, 1996). 
i 
"'f. 
r 
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Table 1 shows some substrates of these isoenzymes, table 2 shows the different inhibitory 
qualities of the different SSRis and table 3 shows some other drugs that also inhibit some 
of these isoenzymes. 
Some isoenzymes demonstrate genetic polymorphic distribution e.g. 4-10% Caucasians 
and 5-10% Mexican Americans are poor metabolisers at the CYP 2D6 site and 3-5% 
Caucasians, 18-23% African Americans and 8% Africans are poor metabolisers at the 
CYP 2C 19 site. These groups of people would be at increased risk of adverse effects if 
they use drugs requiring metabolism by these isoenzymes (Ereshefsky et al., 1996, 
Nemerof et al., 1996). This would apply to paroxetine, sertraline, citaloprarn and 
fluoxetine. 
Drugs with narrow therapeutic windows e.g. tricyclic antidepressants, theophylline, 
phenytoin, tolbutamide, carbarnazepine, terfenadine, astemizole, type 1 C antiarrhythmics 
and antipsychotics should be administered with caution in the presence of SSRis. Genetic 
polymorphism hinders the prediction of clinically significant interactions (Nemerof et al., 
1996). SSRis also have widely differing drug interaction potentials across the CYP 
isoenzyme systems (Ereshefsky et al., 1996). 
Enzyme inhibition is not the only mechanism whereby SSRis interact with other drugs. 
SSRis are highly protein bound, ranging from 80% for fluvoxarnine to 99% for sertraline, 
so if administered with other highly protein bound drugs e.g. warfarin, digoxin, the 
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effects of these drugs are likely to be enhanced and require dose adjustment (Newhouse, 
1996, Preskom, 1997). 
There are also drug interactions where the underlying mechanism is unclear e.g. 
'serotonin syndrome' reported following use of a SSRI in conjunction with a monoamine 
oxidase inhibitor (Skerritt et al., 1997). 
These interactions are important in the elderly because they are more likely to have 
another illness requiring medication and they are the population in which polypharmacy 
is a problem. 
CYP2D6 CYP 3A3/4 CYP 1A2 CYP2C9 CYP2Cl9 
Fluoxetine Sertraline Amitriptyline Warfarin Imipramine 
Paroxetine Amitriptyline Clomipramine Phenytoin Clomipramine 
Sertraline Clomipramine Imipramine Tolbutamide Citalopram 
Venlafaxine Imipramine Caffeine Diclofenac Diazepam 
Amitriptyline Alprazolam Clozapine Mefenamic acid Omeprazole 
Clomipramine Triazolam Theophylline Piroxicam Propranalol 
Desipramine Midazolam Propranalol Naproxen Hexobarbital 
Nortryptiline Diazepam Paracetamol Ibuprofen Mephenytoin 
Clozapine Clozapine Warfarin 
Risperidone Terfenadine 
Thioridazine Astemizole 
Perphenazine Loratadine 
Propranalol Cisapride 
Metoprolol Omeprazole 
Timolol Diltiazem 
Encainide Verapmil 
Flecainide Nifedipine 
Propafenone Carbamazepine 
Codeine Erythromycin 
Cyclosporine 
Lidocaine 
Cocaine 
Quinidine ! I 
Tamoxifen 
Cortisol 
Testosterone 
Oestradiol 
Progesterone 
Paracetamol 
Table 1. Some substrates of CYP isoenzymes. 
1 
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Inhibition CYP2D6 CYP 3A3/4 CYPIA2 CYP2C9 CYP2CI9 
ootencv 
High Fluoxetine Fluvoxamine Fluvoxamine Fluoxetine Fluvoxamine 
Paroxetine Fluvoxamine 
Moderate to low Sertraline Fluoxetine Fluoxetine 
Citalopram 
Low to minimal Fluvoxamine Sertraline Fluoxetine 
Paroxetine Paroxetine 
Citalopram Sertraline 
Citalopram 
Unknown Paroxetine Paroxetine 
Sertraline Sertraline 
Citalopram Citalopram 
Table 2. Cytochrome P450 inhibition by different SSRis including potency. 
CYP2D6 CYP3A3/4 
Quinidine Ketaconazole 
Fluphenazine Erythromycin 
Haloperidol Nefazodone 
Thioridazine 
Amitriptyline 
Desipramine 
Clomipramine 
Table 3. Other drugs that inhibit Cytochrome p450 isoenzymes. 
3.0 The physiology of Arginine Vasopressin 
Arginine Vasopressin (AVP, also known as antidiuretic hormone) is synthesised as a 
portion of a large precursor protein from which A VP and Oxytocin are cleaved (Rinaman 
et al., 1995). It is comprised of 9 amino acids as follows (Jackson, 1996): 
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Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly(NH2) 
A number of vasopressin-like substances occur naturally, they are all nonapeptides 
(Jackson, 1996). A VP is synthesised in the perikarya of magnocellular neurons, which 
occur in four major clusters in the supraoptic (SON) and paraventricular nuclei (PVN) of 
the hypothalalmus as well as in smaller groups in the accessory nuclei of the anterior 
hypothalamus. Long axons of these neurons take a loop-like pathway through the lateral 
retrochiasmic area, entering the median eminence and then run in the internal layer of this 
structure to terminate in the neurohypophysis. These neurons respond to osmotic stimuli 
(Antoni, 1993, Aguilera, 1994, Rinarnan et al., 1995, Jackson, .1996). The process of 
axonal transport of vasopressin-containing granules is rapid taking about 30 minutes from 
stimulus to newly synthesised hormone arriving at the posterior lobe (Jackson 1996). 
A VP is released from the neurohypophysis into the peripheral circulation. 
AVP is also synthesised in neurons, mostly in the caudal PVN, that have central axonal 
projections. These are the 'parvicellular' neurons. An important group are the 
corticotrophin release hormone (CRH) neurons that also synthesise and secrete AVP. 
These neurons terminate in the m.edian eminence secreting A VP into the pituitary portal 
system. Other centrally projecting A VP neurons have their perikarya in the stria 
terrninalis, dorsomedial suprachiasmic nucleus, septal area, medial amygdala and locus 
coeruleus. The limbic structures, such as the lateral septum and amygdala, are 
particularly heavily innervated with A VP fibres. In the rat specific areas of innervation 
have been identified and they include the subparaventricular zone, dorsomedial nucleus 
of hypothalamus, medial and lateral preoptic areas, midline thalamic nuclei, habenular 
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nucleus, lateral septum, medial amygdala, periaqueductal grey area and ventral 
hippocampus. There are thus two different populations of A VP secreting neurons, the 
'magnocellular system' projecting to the posterior pituitary and the 'parvicellular system' 
projecting to central brain areas. These two systems may have common and separate 
stimuli for A VP release. The afferent innervation of the PVN is very complex and it is 
not clear whether there is separate innervation of magnocellular and parvicellular neurons 
(Rinaman et al., 1995). 
In healthy adults the principal stimulus for AVP secretion is increased plasma osmolality. 
Severe hypovolaemia and hypotension are also powerful stimuli. Pain, nausea, hypoxia, 
and several endogenous hormones modify A VP secretion (Jackson, 1996). With osmolar 
stimulation, the threshold for secretion is approximately 280 mOsm/kg. Above this A VP 
levels rise in a steep linear fashion (Johnson et al., 1994, Jackson, 1996). Osmolality 
above 290 mOsm/kg leads to an intense thirst sensation (Jackson, 1996). The 
magnocellular neurons in the SON and PVN of the hypothalamus respond directly to 
changes in osmolality, but also have afferent inputs from the subfornix and lamina 
terminalis (Jackson, 1996). 
A VP release is also stimulated by reductions in blood volume and arterial blood pressure. 
A VP at high concentrations (40 times that required for antidiuresis) is a potent 
vasoconstrictor preventing haemodynamic collapse in conditions of hypovolaemia or 
hypotension (Rinaman et al., 1995). The neuronal pathways involved are completely 
different to those involved with the osmoreceptors. Baroreceptors located in the left 
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atrium, left ventricle, and pulmonary veins sense blood volume. Baroreceptors in the 
carotid sinus and aorta sense arterial blood pressure. Information is relayed to the 
supraoptic nucleus via the vagus nerve, glossopharangeal nerve, solitary tract and caudal 
ventrolateral medulla. The relationship between blood volume / pressure and A VP release 
is exponential. This does not disrupt osmotic regulation, but resets the threshold for A VP 
secretion and alters the slope of the osmolality vs. A VP level relationship (Johnson et al., 
1994, Jackson, 1996). 
AVP also has a role in the regulation of blood flow to the choroid plexus and the rate of 
cerebrospinal fluid (CSF) production. Normally AVP is found in the CSF at slightly 
higher concentrations than in plasma, this differential concentration being sustained by 
the blood brain barrier. A VP released into brain extracellular fluid diffuses into the CSF 
and there may also be direct secretion into the CSF in the third ventricle (Rinaman et al., 
1995). 
Hormonal and neurotransmitter regulation of A VP secretion is complex and has not been 
fully elucidated. The literature is often contradictory (Jackson, 1996). Agents that seem 
to stimulate AVP secretion inclu4e acetylcholine, histamine, dopamine, glutamine, 
aspartate, cholecystokinin, neuropeptide Y, substance P, vasoactive intestinal polypeptide, 
prostaglandins and angiotensin II. Substances that inhibit A VP secretion include atrial 
natriuretic hormone, gamma-aminobutyric acid and opioids (Jackson, 1996). In the CNS 
A VP acts as a neurotransmitter and neuromodulator participating in acquisition of some 
learned behaviour and acquisition of some complex social processes and in the 
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pathogenesis of specific psychiatric diseases. The exact role of A VP remains 
controversial (Jackson, 1996). 
3.1 AVP, learning and behaviour. 
In rats genetically deficient in AVP (Brattleboro rats) or made deficient by central 
administration of an A VP antiserum there is inferior performance in learning tasks. 
Experiments evaluating memory by administering A VP and oxytocin peripherally led to 
assumptions that oxytocin is 'amnestic' and AVP is 'memory enhancing'. These findings 
are difficult to interpret because any memory effects may have been related to the 
aversive visceral arousal induced by A VP. Furthermore only 0.002% of subcutaneously 
administered A VP reaches the CSF and concentrations in the limbic brain are unaffected. 
The two suggested effects potentiated by A VP in rats are social recognition and learned 
behaviour (Dantzer & Bluthe, 1993, Engelmann et al., 1996). Centrally administered 
A VP to the septal area of rats has been shown to improve social recognition in males but 
it impairs their navigation in a maze, both processes involving memory. AVP 
administered in the septal area appears to be involved differentially in different behaviour 
tests. Intracerebrally administered A VP and oxytocin are involved in behavioural 
performance that is cued by olfactory signals and it appears to be related causally to 
I 
reproduction. Predominantly sexual steroid-dependent vasopressinergic neurons are 
involved in these behavioural paradigms. The situation is further complicated by A VP 
acting on A VP receptors of non-neuronal structures e.g. glial cell or cerebral 
1 
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microvessels, thus indirectly influencing interneuronal communication. Central release of 
A VP and oxytocin is paralleled by peripheral release, which in turn may induce 
metabolic and autonomic alterations that may support the effects triggered by the central 
peptides. These synergisms at different levels suggest the peptides themselves may 
provide the link between arousal, attention, emotion, learning, memory and behavioural 
performance, thus ensuring the relevant information is acquired and behavioural 
strategies established, stored and reactivated. The acquisition and early processing of 
information seems more sensitive to A VP and Oxytocin than the storage and recall and 
these peptides are predominantly involved in the emotional evaluation of incoming 
information (Engelmann et al., 1996). 
3.2 Stress and A VP secretion. 
The normal physiological response to acute stress is activation of the hypothalamic-
adrenal-pituitary axis resulting in elevated circulating glucocorticoids and glucocorticoid 
negative feedback to the hypothalamus and pituitary. Among the PVN parvicellular 
nuclei there are two populations of cortico-trophic hormone (CRH) neurons. One 
expresses pro-A VP peptides and the other does not. These populations are 
topographically separate and are possibly under separate control. The former is a 
probable source of portal A VP as A VP and CRH occupy the same secretory granules 
(Antoni, 1993, Aguilera 1994). A VP and CRH are released from the median eminence 
into the pituitary portal blood system and carried to the anterior lobe of the pituitary 
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gland stimulating adreno-corticotrophic hormone (ACTH). A VP binds VI b receptors and 
potentiates CRH-induced ACTH secretion. ACTH stimulates release of glucocorticoid 
from the adrenal glands (Rinaman et al., 1995, Aguilera, 1994). It has been hypothesised 
that A VP is the dynamic component in the A VP/CRH combination that stimulates ACTH 
release because A VP receptor and secretion changes, rather than CRH receptor and 
secretion changes, parallel the changes in ACTH responsiveness. CRH may give a 
trophic or permissive signal allowing the action of AVP. During chronic stress the ACTH 
response is altered and this is determined by the A VP:CRH secretion ratio. With chronic 
stimulation of the HP A axis there is marked enhancement of A VP production and only a 
small change in CRH production by parvicellular neurons (Antoni, 1993, Aguilera, 
1994 ). The concentration of pituitary portal A VP is at least one order greater than 
circulating A VP secreted by the magnocellular neurons in response to osmotic stimulus 
suggesting the A VP involved in ACTH regulation is provided directly from the posterior 
pituitary or median eminence, however, this is not clear as there is evidence suggesting 
A VP is released from the axons of the magocellular neurons as they pass through the 
internal zone of the median eminence. The A VP may gain access to the pituitary portal 
circulation through the fenestrated capillaries of the subependymal plexus. (Antoni, 1993, 
Aguilera, 1994 ). If this is the case then there is overlap of A VP released in response to 
osmotic stimuli and ACTH regulation. With chronic stress glucocorticoid levels are 
elevated and glucocorticoid feedback regulating this increase is impaired so the elevated 
glucocorticoid levels are maintained. Implicit in this is that A VP levels may also remain 
elevated because of impaired glucocorticoid feedback. Magnocellular and parvicellular 
cells in the SON contain type II (glucocorticoid preferring) corticosteroid receptors 
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suggesting direct action of glucocorticoids on the regulation of A VP (Antoni, 1993, 
Dinan, 1994). These type II receptors are implicated in the co-ordination of behavioural 
and endocrine responses to stressful stimuli, particularly the hypothalamic-pituitary-
adrenal axis response (Dinan, 1994). In contrast to chronic stress, with chronic osmotic 
stimulation ACTH secretion is inhibited despite high circulating levels of AVP. This is 
probably due to diminished parvicellular PVN activity and down-regulation of pituitary 
A VP receptors (Aguilera, 1994). It stands to reason that the stress that is often an integral 
part of mental illness alters A VP secretion, increasing vulnerability to impaired control of 
water and electrolyte balance. In depression it has been established that a significant 
number of patients hypersecrete cortisol due to overactivity of the hypothalamic-
pituitary-adrenal axis (Dinan, 1994). An interesting hypothesis is this hypersecretion of 
cortisol is due to increased secretion of A VP from the parvicellular neurons. In 
depression basal serum A VP concentration, the release of A VP in response to osmotic 
stress and A VP response to apomorphine have all been observed to be decreased and in 
mania the reverse has been found (Legros et al., 1993 ). This reflects a blunted response 
from the magnocellular neurons. 
3.3 A VP action at receptor level. 
There are two principal types of AVP receptors in the human body, Vl and V2. Vl 
receptors are subclassified as Vla and Vlb. Via are most widespread being found in 
smooth muscle, myometrium, bladder, adipocytes, hepatocytes, platelets, renal medullary 
i 
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interstitial cells, vasa recta in the renal microcirculation, epithelial cells in the renal 
cortical collecting duct, spleen, testis and many CNS structures. V 1 b receptors seem to 
occur only in the adenohypophysis. V2 receptors are mainly found in the renal collecting 
duct system (Rinaman et al,. 1995, Jackson, 1996). The affinity of V 1 b receptors for 
A VP are one order greater in magnitude than V2 receptors and this may be important for 
differential activation of these receptors by circulating AVP (Aguilera, 1994). The 
kidneys are exquisitely sensitive to AVP, with the main antidiuretic function of AVP 
being mediated via the V2 receptors. The exact function of V 1 a receptors in the kidney is 
unclear, except for involvement with prostaglandin synthesis. Under normal conditions 
the walls of the collecting duct system are impermeable to water allowing the passage of 
dilute urine. With A VP secretion, water permeability of the collecting duct system is 
increased. The osmotic gradient between the hypotonic urine and the hypertonic 
interstitial fluid drives the flux of water from the urine thereby diluting the serum 
(Johnson et al., 1994, Jackson, 1996). 
The mechanism of V2 receptor-effector coupling is as follows. The V2 receptor is linked 
to a stimulatory G-protein, which activates adenyl cyclase. Cyclic adenosine-3.5-
monophosphate(cAMP) levels r{se activating cAMP-dependent protein kinase A. By an 
unknown mechanism there is an increased rate of exocytosis of water channel-containing 
vesicles into the apical membrane of the renal collecting duct cells and a decreased rate 
of endocytosis of these vesicles from the membrane. This increases the number of active 
water channels in the membrane thereby increasing water permeability. Urea transporters 
are also activated although this seems to be a separate system to the water channels as it 
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is confined to the inner medullary collecting duct, which allows larger osmolality to 
develop in the inner medullary collecting duct, increasing the urine concentrating ability 
of the kidney (Jackson, 1996). The V2 receptors also mediate sodium transport mainly in 
the cortical collecting duct by activation of existing channels and by insertion into the 
membrane of sodium channel-containing vesicles. Activation of V2 receptors also 
increase circulating levels of procoagulin factor VIII and von Willebrand factor (Jackson, 
1996). 
The VI receptor is also linked to a G-protein. When AVP binds to the receptor, the G-
protein mediates activation of phospholipase C, which hydrolyses phosphatidylinositol-
4.5-bisphosphate generating inositol-1.4.5-triphosphate (IP3) and diacyl-glycerol (DAG). 
IP3 binds to receptors on Ca2+ channels of intracellular Ca2+ stores resulting in Ca2+ 
release. There is also influx of extracellular calcium by an unknown mechanism. The V 1 
receptor secondly mediates the activation of phospholipase D, which in turn mediates the 
hydrolysis of other phospholipids to also produce DAG. DAG activates protein kinase C, 
which phosphorylates proteins that contribute to the biological process. The third process 
is the stimulation of phospholipase A2, which mobilises arachidonic acid from membrane 
phospholipids. Arachidonic acid is metabolised to prostaglandins and 
epoxyeicosatrienoic acids (Jackson, 1996). Prostaglandins limit the antidiuretic effect of 
A VP ( Johnson et al., 1994 ). V 1 receptors mediate vasoconstriction particularly in skin, 
I 
skeletal muscle, fat, pancreas and thyroid gland and also to a lesser degree 
gastrointestinal tract, coronary vessels and brain. Furthermore V 1 receptors mediate 
glycogenolysis, platelet aggregation, ACTH release, and growth of smooth muscle cells 
1 
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and at high concentrations stimulation of uterine and gastrointestinal smooth muscle. 
(Aguilera, 1994, Jackson, 1996). 
4.0 Physiological changes in the elderly. 
With aging basal arginine vasopressin (AVP) secretion is increased but volume of 
distribution and clearance is unchanged (Phillips et al., 1984, Johnson et al., 1994). 
Along with this, A VP secretion in response to osmoreceptor stimulation increases 
(Lindeman, Van Buren & Raisz, 1960, Helderman et al., 1978). In subjects over 75 years 
the relationship between plasma A VP and osmolality breaks down and A VP secretion is 
probably increasingly determined by baroreceptor input. This apparent loss of osmotic 
regulation of A VP secretion may be due to age related involutional changes in the 
neurohypohysis (Johnson et al., 1994). This picture is complicated because baroreceptor 
function is also compromised with aging. Rowe et al. ( 1982) reported there is reduced 
AVP secretion in response to baroreceptor stimulation. Normally a hypertonic saline 
infusion increases blood volume, pressure and pulse. The raised pulse and blood pressure 
dampen A VP secretion in response to the osmolar stimulus. With an age-related defect in 
baroreceptor mediated input to the hypothalamus this dampening effect is ameliorated, 
allowing unrestrained response to changes in osmolality. So despite an increase in blood 
volume and pressure, A VP will be secreted in response to the rising osmolality, resulting 
in water retention and further hypertension (Rowe et al., 1982). 
, 
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Other physiological changes associated with aging also place the elderly at risk of 
developing hyponatraemia. Renal concentrating ability (Lindeman et al., Van Buren & 
Raisz, 1960, Phillips et al., 1984), glomerular filtration rate and renal blood flow are 
reduced (Rowe, 1992). The aging kidney has a salt losing tendency which is caused by 
nephron loss, with increased osmotic load per nephron leading to mild osmotic diuresis 
(Rowe, 1992). Furthermore there is increased secretion of atrial natriuretic hormone and a 
less active renin-aldosterone system (Ohashi et al., 1978). The kidneys' ability to regulate 
salt balance under stress is compounded by similar abnormalities in water balance. The 
elderly therefore have a blunted capacity to conserve water and excrete concentrated 
urine (Rowe, 1992). Renal factors are thus also responsible for impaired water and 
electrolyte control. Moreover, the subjective sensations of thirst are reduced, 
compromising fluid intake after dehydration (Phillips et al., 1984). The accepted normal 
range for serum osmolality in the elderly is 260-309 mOsm/1 as compared with a range of 
281-297 mOsm/1 in healthy adults (Hodkinson, 1977). 
4.1 Hyponatraemia in the elderly. 
Hyponatraemia in the elderly is a common phenomenon. Miller et al. (1996) found a 
prevalence of 8% and a two-year incidence of 11.4% in ambulatory geriatric populations. 
In a nursing home population the prevalence for hyponatraemia was 18% of which 81 % 
were mild (130-134 mmol/1) and the rest moderate (125-129 mmol/1). The one-year 
incidence was 53% of which 67% were mild, 28% moderate and 5% severe (~124 
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mmol/1). (Miller et al., 1995, Miller et al., 1996). A prevalence of 8.6% of serum sodium 
below 13 7 mmol/l was reported in an elderly population living at home with no acute 
illnesses (Caird et al., 1973). In a sample of 120 patients with chronic illnesses of which 
75% were older than 65 years, 22.5% of had a serum concentration below 135 mmol/1 on 
three occasions (mean sodium concentration was 120 mmol/1) during a six month period. 
Of those individuals 75 %were symptomatic albeit with non-specific complaints 
(Kleinfeld et al., 1979). 
4.2 Complications of hyponatraemia 
Symptoms are more common with hyponatraernia in the setting of normal or increased 
extracellular volume and are principally due to movement of water into the brain. These 
symptoms and signs usually occur only when the serum sodium concentration is below 
120 mmol/l, or more typically around 112 mmol/1, and they include headache, confusion, 
restlessness leading to drowsiness, myoclonic jerks and generalised seizures (Tomson, 
1994 ). The brain oedema associated with hyponatraemia can lead to several secondary 
conditions such as pulmonary oedema, central diabetes insipidus and mellitus, cerebral 
infarction, cortical blindness, persistent vegetative state, respiratory arrest and coma. 
Permanent brain damage or death may occur (Fraser & Arieff, 1997). Acute 
hyponatraemia, occurring in less than 12 hours, is associated with a high mortality rate. 
In a series of acute hyponatraemia in 14 subjects reported by Arieff et al. (1976) the 
mean sodium concentration was 112 mmol/1 and half of them died. They found in chronic 
j 
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hyponatraemia symptoms were correlated with more severe hyponatraemia, mean sodium 
concentration of 115 mmol/l vs. a mean sodium concentration of 122 mmol/1 in 
asymptomatic patients. In an animal model symptoms were correlated with the interplay 
between net increase in brain water vs. loss of brain electrolytes. Even in chronic 
asymptomatic hyponatraemia there was a significant increase in brain water (Arieff et al., 
1976). In one series of seven patients, three died and two suffered permanent paralysis 
(Ashraf et al., 1981 ). Central pontine myelinolysis is another complication that is thought 
to be due to too rapid correction of hyponatraemia It is seen in experimental animals, but 
is rare in humans (Ayus et al., 1982, Kovacs & Robertson, 1992, Fraser & Arieff, 1997). 
4.3 Causes of Hyponatraemia. 
Hyponatraemia can occur in three settings of extracellular volume namely normal, 
decreased or increased (Tomson, 1994). The causes in each of these setting are listed in 
table 4. 
NORMAL EXTRACELLULAR VOLUME 
Abnormal A VP release 
Vagal neuropathy 
Deficiency of ACTH 
Hypothyroidism 
Severe potassium depletion 
SIADH 
Stress 
Surgery 
Nausea 
Major psychiatric illness 
Psychogenic polydipsia 
Non-osmotic A VP release 
Increased sensitivity to A VP 
Chlorpropamide 
Tolbutamide 
A VP-like substances 
Oxytocin 
DDAVP 
Unmeasured osmotically active substances stimulating 
osmotic A VP release 
Glucose 
Alcohol 
Mannitol 
Sick cell svndrome 
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DECREASED EXTRACELLULAR VOLUME 
GIT 
Vomiting 
Diarrhoea 
Haemorrhage 
Kidney 
Osmotic diuresis 
Excessive use of diuretics 
Adrenocortical insufficiency 
Tubulo-intestinal renal disease 
Unilateral renal artery stenosis 
Recovery phase of acute tubular necrosis 
: INCREASED EXTRACELLULAR VOLUME 
Heart failure 
Liver failure 
Oliguric renal failure 
Hypoalbuminaemia 
Table 4. Causes of hyponatraemia. (Tomson, 1994) 
4.4 Syndrome of Inappropriate Antidiuretic Hormone (SIADH). 
Hyponatraemia in the elderly is thought most often to be due to the syndrome of 
inappropriate antidiuretic hormone secretion (SIADH). Miller et al. (1996) found in 59% 
I 
of elderly subjects developing hyponatraemia it could be attributed to SIADH (Miller et 
al., 1996). The criteria for SIADH devised by Bartter and Schwartz (1967) require the 
presence of hyponatraemia, plasma hypo-osmolality and urine less than maximally dilute. 
t 
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The following need to be excluded: hypovolaemia, hypotension, renal, adrenal or thyroid 
insufficiency, congestive cardiac failure, nephrosis, cirrhosis, or other disorders resulting 
in generalised oedema (Bartter & Schwartz, 1967). This is not necessarily due to 
inappropriate secretion of A VP, but may be due to erratic secretion of A VP independent 
of osmoreceptor function, or resetting of the osmostat, or an A VP 'leak', or due to an as 
yet unidentified antidiuretic substance (Kovacs & Robertson, 1992). Furthermore it may 
also be due to abnormal renal response to A VP. Raised serum A VP levels do not 
necessarily result in plasma hypotonicity because in normal individuals this will be 
counteracted by lack of thirst and reduced fluid intake. To cause hypotonicity, excessive 
fluid intake accompanies the raised AVP. Converse to SIADH, inadequate AVP secretion 
or insufficient response by the kidneys results in Diabetes Insipidus. Water conservation 
is impaired and large volumes of dilute urine are excreted (Jackson, 1996). 
5.0 Medical conditions associated with SIADH. 
There are numerous medical conditions associated with the development of SIADH. 
These conditions are more prevalent with increasing age and thus in the elderly they often 
occur in the context of already precarious physiological function. The commonly 
associated conditions are conveniently divided into five categories: A VP producing 
tumours; pulmonary diseases; central nervous system disorders; general surgery and 
drugs {Table 5) (Kovacs & Robertson, 1992). A proportion are idiopathic, especially in 
the elderly (Miller et al., 1996). The usefulness of the concept of SIADH has been 
, 
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questioned because many disorders present with a similar biochemical picture but have 
widely differing aetiologies (Kennedy et al., 1978). 
Tumours 
Bronchogenic Carcinoma 
Uterine Carcinoma 
Mesothelioma 
Proststatic Carcinoma 
Thymoma 
Lymphoma 
Duodenal Carcinoma 
Leukaemia 
Pancreatic Carcinoma 
Nasopharangeal Carcinoma 
CNS Disease 
Mass lesions 
Inflammatory disease 
Degenerative disease 
Other 
Pulmonary Disease 
Infections 
Ventilatory 
General Surgery 
Tumours 
Brain abscess 
Subdural 
Haematoma 
Encephalitis 
Meningitis 
SLE 
Acute intermittent porphyria 
Guillain Barre 
Spinal cord lesions 
Subarachnoid haemorrhage 
Head trauma 
DT's 
Pituitary stalk lesion 
Hydrocephalus 
Tuberculosis 
Pneumonia 
Aspergillosis 
Empyema 
Acute respiratory failure 
Chronic obstructive airways disease 
Positive pressure ventilation 
Drugs 
Chlopropamide 
Cyclophosphamide 
V incristine 
Rampril 
Lisinopril 
Furosemide 
Thiazide 
Morphine 
Barbiturate 
NSAID 
Antidepressant 
Antipsychotic 
Carbaniazepine 
Lipid lowering agent 
Nicotine e.g. smoking 
Other 
AIDS & AIDS related complex 
Table 5. Diseases and Drugs associated with SIADH (Kovacs & Robertson 1992). 
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6.0 Drugs and A VP. 
Drugs are probably the most common cause of SIADH and among those used in 
psychiatry: carbamazepine, all classes of antidepressants, antipsychotics and anxiolytics 
have been implicated. However, there are no accurate estimates of incidence because the 
majority of reports are of single cases, which in itself suggests an idiosyncratic reaction 
(McAskill & Taylor, 1997). It is thus for example, not possible to compare the incidence 
ofhyponatraemia associated with selective serotonin re-uptake inhibitors (SSRis) to that 
of other drugs e.g. tricyclic antidepressants. 
The mechanism by which drugs affect vasopressin secretion varies. Some drugs have 
direct effects on one or more CNS structures that regulate A VP secretion whereas other 
drug indirectly affect A VP secretion by altering blood volume, blood pressure, pain or 
nausea. In most cases the mechanism is unknown. Drugs that stimulate vasopressin 
secretion include vincristine, cyclophosphamide, tricyclic antidepressants, nicotine, 
epinephrine and high doses of morphine. Lithium enhances secretion of A VP, but inhibits 
the renal effects. Ethanol, phenytoin, low dose morphine, glucocorticoids, fluphenazine, 
haloperidol, promethazine all inhibit A VP secretion. Carbamazepine inhibits vasopressin 
secretion centrally, but promotes water retention by direct action on the kidneys. Non 
steroidal anti-inflammatory drugs enhance the antidiuretic response to A VP by reducing 
prostaglandin production thereby removing the inhibitory effects of prostaglandin. 
(Jackson, 1996). 
' 
' 
6.1 SSRis, hyponatraemia and A VP. 
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There have been numerous case reports in the literature of the association between 
hyponatraemia and the use of SSRis. Liu et al. (1996) analysed 30 published case reports 
and 706 cases reported to monitoring bodies and the pharmaceutical industry in North 
America. They found that 55.7% of cases were 65 years and older; 60.3% were female 
and the median onset time was 13 days. Withdrawal of SSRis when reported resulted in 
correction of the serum sodium (Liu et al., 1996), the mean recovery time after 
withdrawal was 9.2 days in several cases (reported in 21 of the 30 cases). In all these 
cases the blood and urine osmolality and sodium concentration, when reported, were 
compatible with the SIADH. Several subjects had concomitant conditions associated with 
SIADH and none had other causes ofhyponatraemia rigorously excluded according to the 
criteria of Bartter and Schwartz (1967). 
The Australian Adverse Reactions Advisory Committee (ADRAC, 1996) published data 
from 33 reports ofhyponatraemia associated with SSRis. The age of subjects ranged 
between 71.5 - 80 years with a 76% female preponderance. Serum sodium levels ranged 
between 111 - 123 mmol/1 (ADRAC, 1996). 
The argument for a causal relationship between SSRis and hyponatraemia is strengthened 
by reports by Cohen et aL, (1990), Jackson et. al. (1995) and Flint et. al. (1996) of three 
patients who were rechallenged with a different SSRI and again developed 
hyponatraemia. However, Staab et al. (1990) report rechallenging a 59 year man with the 
,. 
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same SSRI without recurrence of hyponatraemia. This would need further research for 
clarification. A causal relationship cannot be excluded if a patient did not re-develop 
hyponatraemia as it could be argued that exposure to a SSRI is protective or sensitising. 
Serum fluoxetine and vasopressin levels above normal ranges have been recorded in two 
elderly women who had developed hyponatraemia (Girault et al., 1997). As the authors 
suggest, this could be explained by impaired elimination of fluoxetine and impaired 
control of vasopressin secretion. They go further to suggest a causal relationship between 
impaired fluoxetine elimination, raised serum fluoxetine and control of vasopressin 
secretion. If this hypothesis is true then raised serum fluoxetine levels may be predictive 
of hyponatraemia. The effect of SSRis on A VP secretion has not been clearly established 
and a lot of information is contradictory, for example in obsessive compulsive disorder 
fluoxetine has been noted to decrease A VP synthesis (Legros et al., 1993) 
In the literature search conducted no figures were found for the incidence of 
hyponatraemia in the elderly with mental illness. Pillans and Coulter (1994) calculated 
the incidence of hyponatraemia associated with fluoxetine based on a number of 
spontaneous reports received during a four-year post-marketing event monitoring study. 
These rates were 5.4 per 1000 for patients over 65 years and 8.4 per 1000 women over 65 
years (Pillans & Coulter, 1994). In their review Thomas and Verbalis (1995) quote these 
I 
same figures except tenfold greater i.e. 5.4 per 100 and 8.4 per 100 respectively. As 
recently highlighted by Bouman et al., ( 1997) systematic epidemiological and clinical 
studies are lacking. What is not clear from any of these studies is whether SSRis affect 
1 
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AVP secretion, another aspect of AVP regulation or the renal end-organ effects of AVP. 
Most information about hyponatraemia associated with SSRis has been case studies and 
anecdotal evidence. This kind of evidence identifies the presence of the problem and 
allows only speculation because information is incomplete and confounding variables are 
never excluded. These reports of hyponatraemia need to be put in the context of 
widespread, mostly uneventful use of SSRis. 
7 .0 Psychiatric illnesses, hyponatraemia and A VP. 
Psychiatric morbidity is also associated with hyponatraemia. A prevalence of 10.5% was 
recorded in one study of a psychiatric inpatient population. Of these, 7 5% had 
schizophrenia and the remainder included all other psychiatric illnesses except the 
neuroses (Ohsawa et al., 1992). Earlier age of onset of psychiatric disorder, duration of 
psychiatric disorder, and prolonged admission were associated with a higher incidence of 
hyponatraemia. The A VP secretion in response to osmolar stimulation was reduced in 
patients with schizophrenia indicating abnormal function of the A VP system (Ohsawa et 
al., 1992). A case of SIADH occurring during a psychotic episode in a patient who was 
taking no medications and had no evidence of other conditions associated with SIADH 
was reported by Dubovsky et a/.,(1973). In this case the SIADH recurred during a second 
psychotic episode and resolved with remission of the psychosis. It has been found that in 
patients with Alzheimer's disease the control of AVP release is impaired with CNS and 
CSF A VP levels being raised. Alterations in A VP secretion have also been observed in 
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anorexia, obsessive compulsive disorder, obesity, depression, mania and alcoholism 
(Demitrack et al., 1989, Legros et al., 1993, Rinaman et al., 1995). Most of these reports 
are case studies or involve small samples and these findings are cannot be generalised to 
other people with mental illness. They do serve to illustrate that mental illness can affect 
A VP secretion and function. It must also be borne in mind that most people with mental 
illness probably have normal A VP secretion and function. 
8.0 Sex hormones, A VP and hyponatraemia. 
Premenopausal women have been noted to be at substantially greater risk of dying or 
developing permanent brain damage from symptomatic hyponatraemia than either 
postmenopausal women or men of any age. Female sex hormones have an inhibitory 
effect on brain Na+-K+ ATPase pump action. Female sex hormones have been shown to 
affect plasma levels of A VP. In rats plasma A VP levels vary with stages of the female 
menstrual cycle. Orchidectomy in male rats is associated with increased A VP levels and 
if testosterone is administered the A VP levels fall (Fraser & Arieff, 1997). By this 
argument the low levels of oestrogen and progesterone in elderly women means sex 
hormones should not increase their risk of developing hyponatraemia or its 
complications. 
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9.0 Statement of the problem. 
In swnmary, there are two AVP systems in the CNS, the magnocellular and parvicellular 
systems both situated predominantly in the hypothalamus ( diagram I . ). The former 
responds to osmotic and baroreceptor stimuli by releasing A VP from the 
neurohypophysis into the peripheral circulation. The latter innervates the CNS, especially 
the limbic area. An important group of neurons are the CRH neurons that secrete CRH 
and A VP from the median eminence into the pituitary portal system resulting in ACTH 
release. A VP in the limbic area seems to be involved in the complex process of emotional 
evaluation of incoming information. The 'magnocellular' and 'parvicellular' systems 
probably are under separate control although there is evidence of overlap. 
A VP exerts a strong action on the renal collecting duct increasing water re-absorption. 
Maintenance of water balance depends on many processes including renal physiology, 
AVP, thirst sensation and blood pressure all working synergistically. Defects in one 
process are normally compensated for. In the elderly physiological changes in the kidney 
and hypothalamus mean several of the processes controlling water balance are 
compromised making them vulnerable to an imbalance. 
The elderly are more likely to develop,medical illnesses and receive drugs that alter AVP 
secretion directly or indirectly. This is confirmed by the higher rate ofhyponatraemia 
found in this population. The elderly with mental illnesses will have these risk factors as 
well as the added risk of the mental illness altering A VP secretion. Depression with its 
i 
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altered glucocorticoid secretion particularly suggests involvement of A VP secretion. The 
observed relationship between SSRis and hyponatraemia in the elderly strengthens the 
hypothesis that they are a group vulnerable to defective A VP secretion. 
The aims of the first part of this paper are to report the published cases of hyponatraemia 
occurring whilst using SSRls from the United Kingdom and specifically focus on cases in 
people 60 years and older. Secondly to re-analyse all case reports in the literature looking 
only at this population. The third aim was to investigate whether dysregulation of 
vasopressin function in the elderly using SSRis is a sporadic or usual phenomenon. 
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METHODS 
Part 1 
A literature search was done using Medline to identify case reports of hyponatraemia 
associated with SSRI use in patients 60 years and older. There were 46 cases identified 
but the information reported was often limited (Hwang & McGraw, 1989, Cohen et al., 
1990, Gommans & Edwards, 1990, Marik et al., 1990, Goddard & Paton, 1992, 
Blacksten & Birt, 1993, Chua & Vong, 1993, Crews et al., 1993, Kazal et al., 1993, 
McHardy, 1993, Ball & Hertzberg, 1994, Druckenbrod & Mulsant, 1994, Llorente et al., 
1994, Pillans & Coulter, 1994, Ayonrinde et al., 1995, Jackson et al., 1995, Leung & 
Remick, 1995, Taylor & McConnell, 1995, Thornton & Resch, 1995, ADRAC, 1996, 
Flint et al., 1996, Kessler & Sameuls, 1996, Ng & Alderman, 1996, Robinson et al., 
1996, Ten Holt et al., 1996, Voegeli & Baumann, 1996, Girault et al., 1997) (Table 6). In 
each case the following information was collected: age, sex, dose of SSRI, time to 
detection ofhyponatraemia, lowest serum sodium level recorded, and time to recovery of 
serum sodium. 
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Hwang& 75 M Fluoxetine 20 10 126 264 417 - 10 
Magraw 1989 
Cohen et al. 82 F Fluoxetine 20 3 125 265 - 74 7 
1990 
Cohen eta/. 79 F Fluoxetine 20 42 129 - - - 5 
1990 
Cohen et al. 79 F Fluoxetine 20 5 128 - - - 5 
1990 
Cohen eta/. 84 F Fluoxetine 40 21 124 264 - 54 14 
1990 
Cohen eta/. 85 M Fluoxetine 20 7 126 272 - 84 14 
1990 
Gommans& 75 F Fluoxetine 20 12 116 242 337 91 6 Drowsiness, 
Edwards confusion 
1990 
Goddard& 69 F Paroxetine 20 16 126 - - - 2 Drowsiness, 
Paton 1992 lethargy 
Blacksten & 92 F Fluoxetine 20 13 98 214 465 114 8 Weakness, 
Birt 1993 loss of 
appetite, 
lethargy 
Chua& 78 F Paroxetine - 5 115 256 369 - 10 Confusion 
Vong 1993 
Chua& 76 M Paroxetine - 7 112 246 292 - 4 Confusion 
Vong 1993 
Crews et al. 73 M Sertraline 50 5 118 251 511 33 - Collapse 
1993 
Kazal et al. 83 F Fluoxetine 20 6 124 256 573 85 13 Confusion, 
1993 weakness 
Marik 1993 60 F Fluoxetine - 112 106 225 452 50 14 Drowsiness, 
confusion 
McHardy 70 F Fluvoxamine 100 5 114 239 392 - 6 Confusion 
1993 
Ball et al. 74 F Fluoxetine 20 14 116 - - 42 14 
1994 
Druckenbord 83 F Fluoxetine 40 65 109 242 530 46 28 Agitated 
& Mulsant 
1994 
Llorente et 92 M Sertraline 50 50 5 122 260 361 59 7 
al. 1994 
Pillans & 76 F Fluoxetine 20 13 116 242 337 91 22 Drowsiness, 
Coulter 1994 confusion 
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Pillans & 81 F Fluoxetine 20 8 128 - - - 4 
Coulter 1994 
Pillans & 76 F Fluoxetine 20 19 120 - - - - Lethargy 
Coulter 1994 
Pillans & 88 F Fluoxetine 20 15 121 253 456 - -
Coulter 1994 
Pillans & 68 F Fluoxetine 20 60 120 - - - - Confusion 
Coulter 1994 
Pillans & 87 F Fluoxetine 20 42 114 - - - 21 
Coulter 1994 
Pillans & 84 F Fluoxetine 20 13 117 - - - 10 
Coulter 1994 
Ayonrinde et 67 F Paroxetine 20 7 114 232 372 49 9 Lethargy, 
al. 1995 weakness, loss of 
aooetite 
Jackson et al, 77 F Fluoxetine 20 12 104 216 334 - - Confusion 
1995 
Jackson et al. 77 F Sertraline 50 14 126 246 418 - 3 
1995 
Leung & 87 M Sertraline 50 15 118 - - - 14 Dizziness, 
Remick 1995 nausea& 
vomiting 
collaose 
Taylor& 89 F Sertraline 50 35 112 236 222 51 14 Confusion 
McConnell 
1995 
Taylor& 83 F Fluoxetine 20 35 120 - - - 14 
McConnell 
1995 
Taylor& 73 F Fluoxetine 20 14 118 252 314 - 7 Dizziness 
McConnell 
1995 
Thorton & 60 M Sertraline 50 5 126 256 389 - - Confusion 
Resch 1995 
Thorton & 72 F Sertraline 75 4 105 217 393 - - Confusion 
Resch 1995 
ADRAC 77 F Sertraline 50 5 121 253 482 - 7 Confusion 
1996 
Flint et al. 78 F Paroxetine I() 7 125 - - - 10 
1996 
Flint et al. 78 F Fluoxetine 20 140 118 255 705 23 14 Dizziness, 
1996 weakness, 
lethargy 
Kessler & 82 F Sertraline 50 3 123 - 373. 36 6 
Sameuls 
1996 
Ng& 81 M Sertraline 50 4 120 262 718 - - Confusion 
1 
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Alderman 
1996 
Ng& 76 F Fluoxetine 60 28 118 244 612 13 - Weakness, 
Alderman loss of 
1996 appetite 
Robinson et 70 M Sertraline 50 84 129 ,J.. t - -
al. 1996 
Ten Holt et 78 F Fluoxetine 20 42 103 - 209 - - Drowsiness, 
al. 1996 stupor, 
weakness 
Ten Holt et 73 F Fluoxetine 20 5 110 - 247 - - Lethargy, 
al. 1996 dyspnoea 
Voegli & 73 F Citalopram 20 7 128 - - - 3 
Bauman 1996 
Girault et al. 70 F Fluoxetine 20 30 106 205 420 13 8 Drowsiness, 
1997 confusion 
Girault et al. 81 F Fluoxetine 20 48 104 - - 9 13 Weakness, 
1997 confusion 
Table 6. Cases of hyponatraemia associated with SSRI use in the elderly reported in 
the literature. 
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Computerised records were requested of adverse drug reactions to SSRis from the 
Committee on Safety of Medicines, which is the official monitoring body that collects 
spontaneous reports of side effects of medications from prescribing doctors in the UK. 
Records were requested on fluoxetine, sertraline, paroxetine, citalopram, and 
fluvoxamine. The records included all reports up until 3/12/1996. The following data was 
requested on each drug: age, sex, dose of SSRI, time to detection of hyponatraemia, 
lowest serum sodium level recorded, and time to recovery of serum sodium. Data was 
excluded if the age or sex of the patient was not given or if they were under 60 years of 
age. There were 257 cases ofhyponatraemia associated with SSRis during this period. Of 
these 32 were excluded because of incomplete data, 23 were under 60 years old, and 202 
cases were suitable for analysis. 
Since the data is retrospective and often incomplete, simple descriptive analysis was 
initially performed using Microsoft Excel. Columns were analysed separately so that the 
sample size for each column was the number of cases in which the relevant information 
was available. When comparisons were made of means a two-tailed T-test with unequal 
variance was performed. The Chi squared test was performed to compare contribution 
made to the sample by females and males. 
1 
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Part2 
Subjects were identified by clinicians working in the Department of Mental Health for 
Older People, Homerton Hospital, London. This research project was approved by the 
East London and the City Health Authority Research Ethics Committee. To be included 
subjects had to be 65 years and older and about to be started on sertraline for a depressive 
illness. It was decided to use sertraline on all patients requiring a new SSRI during the 
time of the study to limit confounding variables and it was already a preferred agent of 
most clinicians at the time. If their baseline serum sodium concentration was abnormal 
they were excluded. The decision to treat was made by the responsible clinician. Written 
consent was taken from subjects and they were given an information sheet about the 
study. Nine patients were started on sertraline during the period April to November 1997. 
Three patients were excluded from the trial. One refused to give consent, one was 
demented and thus unable to give consent and the third patient took an overdose during 
the first week of treatment. Medical illnesses, psychiatric illnesses, medication, smoking 
and blood pressure were recorded. Prior to the first dose of sertraline, blood samples were 
taken by venesection in the cubital fossa by the author and a urine sample was obtained 
immediately after blood sampling. These samples were analysed for serum electrolytes, 
urea, creatinine, protein, urate, glucose, thyroid functions, osmolality and urine sodium 
and osmolality in the Chemical Pathology laboratory, Homerton Hospital, London. 
Serum and urine sodium concentrations were determined using the Olympus AU600, an 
automated instrument using ion selective electrodes. Serum and urine sodium 
concentrations were determined by the Osmomat, an automated instrument detecting 
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freezing point with an osmometer. These tests were done to establish baseline sodium and 
osmolality values and to identify other conditions that may cause hyponatraemia 
according to Bartter and Schwartz (1967). Sertraline 50 milligrams, the recommended 
starting dose, was then prescribed. Between days 14 and 21 of treatment blood and urine 
samples were again taken and analysed for serum sodium concentration, serum 
osmolality, urine sodium and urine osmolality. Two subjects' sample were not 
completely analysed by the laboratory and had to be repeated. In one the repeat sample 
was within the 21 day period, the other was not. 
Results were then analysed looking specifically for indicators of altered control of 
vasopressin secretion i.e. hyponatraemia in the context of serum hypo-osmolality and 
urine less than maximally dilute. The serum and urine sodium concentration and 
osmolality prior to and during sertraline treatment was compared using a two-tailed t-test 
for paired data. 
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RESULTS 
Part 1 
In the published case reports of patients 60 years and older developing hyponatraemia 
whilst using SSRls, the mean age was 77.6 years with a standard deviation of 
± 7.2 (Table 7). The mean time to detection was 22.2 days, the range being 3-140 days. 
However the mode was only 5 days. The lowest recorded serum sodium was 98mmol/l 
with a mean of 117.8 mmol/1 and the mean time to normalisation of serum sodium was 
10.2 days. In only three cases (6.5%) was the dose of SSRI greater that the recommended 
starting dose. Of the cases, 80% were female. 
Mean±SD Mode Range 
Age (years) n=46 77.6 ± 7.2 60-92 
Time to detection (days) 22.2 ± 28.4 5 3 -140 
n=46 
Time to normalisation of 10.2 ± 5.8 14 2-28 
serum sodium (days) n=34 
Lowest serum sodium 117.8 ± 8.0 98 - 129 
(mmol/1) n=46 
Sex male=9 females=37 ratio I :4 
Table 7. Results of analyses of all published case reports of hyponatraemia 
associated with SSRI use. 
The 202 cases reported to the Committee on Safety of Medicines had a mean age of 78.0 
years with a standard deviation of ±8 years (Table 8). The mean time to detection was 21 
1 
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days, the range was 1-253 days and the mode 7 days. The mean time to normalisation of 
serum sodium upon cessation of SSRI was 9 days. As in the published case reports, the 
lowest recorded serum sodium concentration was 98 mmol/1 and the mean was 118.0 
mmol/1 (Table 2). In this group, 74% of cases were female. In 31 cases (15%) the dose of 
SSRI was greater than the recommended starting dose. 
Mean±SD Mode Range 
Age (years) n=202 78.0± 8.0 60-98 
Time to detection (days) 21.0 ± 40.0 7 1-253 
n=104 
Time to normalisation of 9.0± 7.0 2 1-32 
serum sodium ( days) n=72 
Lowest serum sodium 118.0 ± 7.0 98-133 
(mmol/l) n=117 
Sex male=53 females=l49 Ratio 1:2.8 
Table 8. Results of analyses of data from the Committee on Safety of Medicines of 
hyponatraemia associated with SSRI use in the United Kingdom. 
The data from the published case reports is very similar to the data from the Committee 
on Safety of Medicines. The latter is a much larger group and therefore has greater 
power, so this group was used for further analysis. The data were re-analysed comparing 
a younger group, 60-69 years, to an older group 70-98 years; females to males; and 
finally the two age groups were further divided by sex comparing the sexes with 
themselves and each other. 
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Table 9. shows the comparison of the younger group, 60-69 years, to the older group, 70-
98 years. 
60-69 years ~70 years P value 
(± SD) n=31 (± SD) n=l 71 
Sex ratio: Female:Male 1.6:1 3.2:1 0.09 
0/o Female 61% 76% 
Age: Mean (years) n= 170 66±3 80±6 
Time to detection: Mean (days) n= 104 40.4 ± 66.4 17.5 ± 31.8 0.19 
Mode (days) 10.0 7.0 
Range (days) 2-253 1-229 
Time to normalisation: Mean (days) n=72 7.7±4.8 9.2 ± 7.1 0.35 
Mode (days) 8.0 2.0 
Range (days) 1 - 16 1 - 32 
Lowest Sodium: Mean (mmol/1) n= 117 119.6 ± 8.8 117.4±7.2 0.37 
Mode (mmol/1) 123.0 118.0 
Range (mmol/1) 103.0-131.0 98.0-133.0 
Table 9. Comparison of age groups 60 - 69 and 70 - 98 years. 
In the younger group 61 % of the sample were female and 76% in the older group were 
female (Chart 1 ). 
1 
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80 -89 yrs 
Ag1 (y11r1) 
Chart 1. Sex distribution in two age groups 
70-98 yrs 
The mean of the time to detection was greater in the in the younger group (p=0.032), but 
the modes were similar. Due to the difference in variance the difference in 
means was not statistically significant (p =0.19). 
The means of the recovery time were not significantly different in the two groups 
(p=0.35), although the mode was lower in the older group. 
There was no significant difference in the means of the lowest sodium concentrations 
between the two age groups (p=0.37). The mean sodium concentrations in both groups 
were in the severe range. 
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Female Male Pvalue 
(n=l49) (n=53) 
Age: Mean (years) 78 ± 7.5 76.4 ± 8.6 0.20 
Time to detection: Mean (days) 17.7 ± 38.2 32.0 ± 43 0.15 
Mode (days) 7 7 
Range ( days) 1-253 2-178 
Time to normalisation: Mean (days) 9.1 ±6.5 8.5 ± 7.7 0.79 
Mode(days) 14 2 
Range (days) 1-32 1-32 
Lowest Sodium: Mean (mmol/1) 117.2 ± 7.3 119.3 ± 7.8 0.21 
Mode (mmol/1) 119.0 122.0 
Range (mmol/1) 98-133 103-130 
Table 10. Comparison of female and male subjects 
Comparing the data for females to males, there was no significant difference in their ages 
(p=0.20) (Table 10). 
The apparently longer time to detection in males did not reach statistical significance 
(p=0.15). The recovery time was similar (p=O. 79). 
There was no significant difference between the means of the lowest sodium 
concentrations between females and males (p=0.21). 
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Female Male Female Male 
60-69yrs 60-69yrs 70-98yrs 70-98yrs 
(n=l9) (n=l2) (n=l30) (n=41) 
Age: Mean (years) 66.4 ± 2.5 64.7 ± 2.9 79.9 ± 6.4 79.8 ± 6.4 
Time to detection: Mean (days) 49.2 ± 87.0 31.5±41.0 14.2 ± 27.4 32.3 ± 45.2 
Mode (days) NIA NIA 7 7 
Range (days) 2-251 6-124 1-229 2-178 
Time to normalisation: Mean (days) 8.3 ± 4.4 7.0± 5.6 9.2 ±6.8 9.2 ± 8.6 
Mode (days) NIA NIA 14 2 
Range (days) 3-13 1-13 1-32 2-32 
Lowest Sodium: Mean (mmol/1) 120.7 ± 8.3 118.4 ± 9.7 116.9 ± 7.2 119.7 ± 7.2 
Mode (mmol/1) NIA NIA 118 122 
Range (mmol/1) 108-131 103-130 98-133 103-130 
Table 11. Comparison of sexes and two age groups 
Male 60-69 vs Female 60-69 Male 60-69 vs Male 70-98 vs 
70-98 yrs vs 70-98 yrs Female 60- Female 70-98 
69yrs yrs 
A2e NIA NIA 0.09 0.99 
Detection 0.97 0.29 0.61 0.14 
Recovery 0.51 0.61 0.66 0.99 
Sodium 0.74 0.24 0.61 0.12 
Table 11. P values of comparison of sexes and two age groups 
Looking at the data split into the two age groups and sexes (Tables 10&11), there were 
no significant differences in age (p=0.09), detection time (p=0.61), recovery time 
(p=0.66), or sodium concentration (p=0.61) in the younger group when comparing 
females to males. In the older group, there were also no significant differences in age 
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(p=0.99), detection time (p=0.14), recovery time (p=0.99) or sodium concentration 
(p=0.12). 
Comparing the younger females to the older females, there were no significant 
differences in the detection time (0.29), recovery time (p=0.61) or sodium concentration 
(p=0.24). Comparing the younger male group to the older male group, there were no 
significant differences in detection time (p=0.97), recovery time (p=0.51) or sodium 
concentration (p=0.74). 
The sample was again divided using the mean age as the dividing point. The younger 
group was now comprised of people 60-78 years old and the older group 79-98 years 
Table 13). Again the female preponderance remained with women making up 77% and 
71 % of the two age groups respectively. There were no significant differences between 
the two age groups in recovery time (p=0.45), or sodium concentration (p=0.65). 
Hyponatraemia was detected significantly earlier in the older group (p=0.03). 
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60-78 years 79-98 years P value 
(± SD) n=l 10 (± SD) n=92 
Sex ratio: Female:Male 2.4 3.4 0.31 
0/o Female 77% 71% 
Age: Mean (years) n=202 71.8 ± 4.6 84.8 ±4.2 
Time to detection: Mean (days)n=104 28.1±51.8 12.7 ± 12.7 0.03* 
Mode (days) 7.0 7.0 
Range (days) 1-253 1-72 
Time to normalisation: Mean (days) n=71 9.3 ± 8.2 8.2 ± 5.4 0.45 
Mode (days) 3.0 14.0 
Range (days) 1-32 1-20 
Lowest Sodium: Mean (mmol/1) n=l 16 117.4 ± 8.2 118.1 ±6.5 0.65 
Mode (mmol/1) 118.0 119.0 
Range (mmol/1) 98-133 103-129 
Table 13. Comparison of age groups 60 - 78 and 79 - 98 years. 
When comparing the males in the two age groups (Tables 13&14), there were no 
significant differences in detection time (p=0.66), recovery time (p=0.76), or sodium 
concentration (p=0.30). The same held true for the females with detection time (p=0.11 ), 
recovery time (p=0.45) and sodium concentration (p=0.80) not significantly different. 
The younger female group did not differ from the younger male group in age (p=0.16), 
detection time (p=0.54), recovery time (p=0.77) or sodium concentration (p=0.53). 
I 
Similarly the older female group did not differ from the male group in age (p=0.62), 
detection time (p=0.23), recovery time (p=0.84) or sodium concentration (p=0.06). 
l 
- 51 -
Female Male Female Male 
60-78yrs 60-78yrs 79-98yrs 79-98yrs 
(n=78) (n=32) (n=71) (n=21) 
Age: Mean (years) 72.3 ± 4.2 70.7 ± 5.4 84.6 ± 4.3 85.1 ± 3.9 
Time to detection: Mean (days) 25.3 ± 54.1 34.1 ±47.6 10.8 ± 8.3 25.7 ±26.8 
Mode (days) 2.0 7.0 7.0 NIA 
Range (days) 1-253 2-178 1-33 4-72 
Time to normalisation: Mean (days) 9.7 ± 7.2 8.8 ± 8.7 8.3 ± 5.5 7.8 ± 5.5 
Mode (days) 8.0 3.0 14.0 8.0 
Range (days) 1-32 1-32 1-20 2-18 
Lowest Sodium: Mean (mmol/1) 117.0 ± 7.9 118.5 ± 8.9 117.4±6.7 121.1 ± 4.4 
Mode (mmol/1) 118.0 130.0 119.0 118.0 
Range (mmol/1) 98-133 103-130 103-129 116-128 
Table 14. Comparison of sexes and two age groups 
Male 60-78 vs Female 60-78 Male 60-78 vs Male 79-98 vs 
79-98 yrs vs 79-98 yrs Female 60-78 Female 79-98 
yrs yrs 
A~e NIA NIA 0.16 0.62 
Detection 0.66 0.11 0.54 0.23 
Recovery 0.76 0.45 0.77 0.84 
Sodium 0.30 0.80 0.53 0.06 
Table 15. P values of comparison of sexes and two age groups 
Symptoms were reported in 29 of the 46 case reports (Table 16). Confusion, weakness, 
lethargy, and drowsiness were most frequently reported. In the cases from the Committee 
on Safety of Medicines, symptoms were poorly reported, however, there were cases of 
seizures, falls and three fatalities. 
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Symptom No. of reports 
Confusion 16 
Weakness 7 
Lethanzv 6 
Drowsiness 6 
Dizziness 3 
Loss of aooetite 3 
Collapse 2 
Stupor 2 
Altltation 1 
Dyspnoea 1 
Nausea & vomitiruz 1 
Table 16. Symptoms reported in 29 out of 46 published case reports. 
Part2 
The cases that were prospectively monitored upon starting sertraline will be presented 
individually. 
Subject 1: 
An 83 year man presented with a, Major Depressive Episode. Four months previously he 
had a stroke. He was receiving treatment for paroxysmal atrial flutter, iron deficiency 
anaemia and benign prostrate hypertrophy. At the time of starting sertraline he was taking 
aspirin, ranitidine, lactulose, ferrous sulphate, ibuprofen, lofepramine, senna and vitamin 
C. He had been receiving these drugs for several months. The lofepramine was stopped 
when the sertraline was commenced. No other new drugs were commenced during the 
two week monitoring period. He smoked 15 cigarettes daily. Prior to commencing 
- 53 -
sertraline his serum potassium, creatinine, total protein, albumin, urate, glucose, and 
thyroid function tests were normal. His urea was raised, 8.7 mmol/1 (2.0-6.6 mmol/1). His 
blood pressure was 155/90. At 14 days follow-up his blood pressure was 150/70, and his 
potassium and creatinine remained normal. His urea was 8.2 mmol/1. His urine and serum 
sodium and osmolality are presented in the table below (Table 17). These were 
essentially unchanged. 
151 Sample 2°0 Sample - day 14 
Serum sodium 134 mmol/1 136 mmol/1 
Serum osmolality 297 mOsm/1 301 mOsm/1 
Urine sodium 95 mmol/1 127 mmol/1 
Urine osmolality 683 mOsm/1 739 mOsm/1 
Table 17. Results of subject 1. 
Subject 2: 
A 73 year woman presented with a Major Depressive Disorder with somatisation. She 
had a background history of breast cancer and tuberculosis both of which she was no 
longer receiving treatment for. She had insulin dependent diabetes, arthritis, hypertension 
and peptic ulcer disease. At the time of commencing sertraline she was also taking 
atenolol, frusemide, aspirin, ranitidine, gaviscon, insulin, lorazepam and senna. Three 
days after commencing sertraline she was prescribed diclofenac sodium and misoprosol 
by her general practitioner. She was a non-smoker. Prior to commencing sertraline her 
serum potassium, urea, creatinine, total protein, albumin, urate, glucose, and thryroid 
function tests were normal. Her blood pressure was 110/70. At 14 days follow-up her 
blood pressure was 120/70, and her potassium, urea and creatinine remained normal. Her 
f 
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urea was slightly rai~ 7 .1 mmoVl. Her urine and serum sodium and osmolality are 
presented in the table below {Table 18). There were no significant changes. 
1st Sample 2na Sample - day 14 
Serum sodium 137 mmoVl 136 mmoVl 
Serum osmolality 310 mOsm/1 303 mOsm/1 
Urine sodium 68mmoVl 151 mmoVl 
Urine osmolality 619 mOsm/1 719 mOsm/1 
Table 18. Results of subject 2. 
Subject 3: 
A 76 year man presented with a Major Depressive Episode with somatisation. He was a 
non-smoker. He was taking digoxin, frusemide and captopril for atrial fibrillation, 
congestive cardiac failure and hypertension, all of which had been started in the prior few 
months. No new drugs were commenced during the two week monitoring period. In his 
initial blood sample his potassium, creatinine, total protein, albumin, urate, and thyroid 
function tests were normal. His urea was elevated a 10.6 mmol/1 in the first sample and 
9.4 mmol/l in the second sample. His glucose was 8.5 mmol/l. The potassium and 
creatinine were unchanged in the second sample. His blood pressure was 160/95 and 
160/100 respectively. His urine ~d serum sodium and osmolality are presented in the 
table below (Table 19). No significant changes occurred. 
151 Sample 2na Sample - day 14 
Serum sodium 140mmoVl 141 mmol/l 
Serum osmolality - 308 mOsm/1 306 mOsm/1 
Urine sodium 145 mmoVl 221 mmoVl 
Urine osmolality 1040 mOsm/1 972 mOsm/1 
Table 19. Results of subject 3. 
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Subject 4: 
A 76 year woman presented with a long standing history of Depressive Disorder with 
generalised anxiety and somatisation. She was a non-smoker. Her medical problems were 
hypertension, arthritis, and renal cysts. She was taking alprazolam, propranalol and 
thioridazine at the time of commencing sertraline. No other drugs were commenced 
during her monitoring period. In her first blood sample the potassium, creatinine, total 
protein, albumin, urate and thyroid function tests were normal. The glucose was raised at 
9.4 mmol/1 and urea at 6.9 mmol/1. Her blood pressure was 170/70 prior to commencing 
sertraline and 140/80 on day 21. Urine and blood samples were taken on four occasions, 
but on two of these the data was incomplete. Her urine and serum sodium and osmolality 
are presented in the table below (Table 20). There were no significant changes. 
1st Sample 2na Sample- 3rd Sample - 4m Sample-
day 12 day 21 day 56 
Serum sodium 137 mmol/1 137 mmol/1 137 mmol/1 137mmol/l 
Serum osmolality 301 mOsm/1 305 mOsm/1 
Urine sodium 65 mmol/1 152 mmol/1 
Urine osmolality 895 mOsm/1 821 mOsm/1 631 mOsm/1 
Table 20. Results of subject 4. 
Subject 5: 
An 80 year woman presented with a Major Depressive episode. She had a background 
history of breast cancer 20 years previbusly for which she was no longer receiving 
treatment. She had a hiatus hernia, asthma and hypothyroidism. Her medication prior to 
commencing sertraline was thyroxine, aspirin and salbutamol. She was a non-smoker. 
Initially her serum potassium, creatinine, total protein, albumin, urate and thyroid 
t 
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function tests were normal and her blood pressure was 150/90. Her urea was 7.3 mmol/1 
and glucose was 7.8 mmol/1 both being marginally raised. At second testing, the 
laboratory omitted to do serum osmolality and the sample was repeated on day 21.Her 
urine and serum sodium and osmolality are presented in the table below (Table 21 ). 
Again no changes were significant. 
1st Sample 2°a Sample - day 3ru Sample-day 
14 21 
Serum sodium 138 mmol/1 138 mmol/1 138 mmol/1 
Serum osmolality 298 mOsm/1 298 mOsm/1 
Urine sodium 46 mmol/1 31 mmol/1 40 mmol/1 
Urine osmolality 610 mOsm/1 486 mOsm/1 707 mOsm/1 
Table 21. Results of subject 5. 
Subject 6: 
A 76 year woman presented with a Major Depressive Episode. She was a non-smoker. 
She had no medical problems. She was on lithium, amitriptyline and sulpiride at the time 
of commencing sertraline. The amitriptyline was stopped the day the sertraline was 
commenced. At initial testing her potassium, urea, creatinine, total protein, urates, 
glucose and thyroid functions were normal and her blood pressure was 140/80. On re-
testing her urea was elevated at 7 .1 mmol/1. Her blood pressure was unchanged. Her urine 
and serum sodium and osmolality are presented in the table below (Table 22). No 
changes were significant. 
, 
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151 Sample 2°0 Sample - day 14 
Serum sodium 139mmol/l 141 mmol/1 
Serum osmolality 291 mOsm/1 294m0sm/l 
Urine sodium 98 mmol/1 34 mmol/1 
Urine osmolality 618 mOsm/1 618 mOsm/1 
Table 22. Results of subject 6. 
In the table below (Table 23) the statistical analyses are presented confirming that there 
were no significant differences in the serum and urine sodium concentration and 
osmolality prior to and during sertraline treatment. 
P value 
Serum sodium concentration 0.24 
Serum osmolality 0.86 
Urine sodium concentration 0.22 
Urine osmolality 0.83 
Table 23. P values of comparisons of serum and urine sodium concentration and 
osmolality prior to and during sertraline treatment. 
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DISCUSSION 
1.0 Results of first study. 
1.1 Age, hyponatraemia and SSRis. 
In the data from the Committee on Safety of Medicines, 90% were 60 years and older. 
This verifies the vulnerability of this population to hyponatraemia. Unfortunately figures 
of total number of scripts written for SSRis over this period and the proportion for people 
over 60 years was not obtained. In their analysis, Liu et al. (1996) used 65 years as the 
cut off age and they found 55. 7 % of subjects were older than this. In the report from 
ADRAC (1996) all 33 cases were over 70 years. They did not specify if they looked 
specifically at this age group. All these studies suggest a trend that the elderly are most 
affected. 
In the two samples, the Committee on Safety of Medicines sample and the published case 
report sample, the mean age of the subjects were 77.6 and 78 years respectively. This 
suggests it is the older elderly most a risk. This is consistent with findings that 
physiological changes that accompany aging are more marked as age progresses. 
Particularly the control of A VP secretion in response to osmoreceptors has been noted to 
be prone to dysregulation after 75 years (Johnson, 1984). Renal changes such as 
{ 
f 
- 59 -
decreased glomerular filtration rate and renal blood flow are also more likely with greater 
age. 
1.2 Detection of hyponatraemia. 
The time to detection ofhyponatraemia had a large range in the two samples i.e. 1 -253 
days. This is probably because the symptoms associated with hyponatraemia are non-
specific and often vague and therefore may be attributed to other reasons. For example, 
weakness, lethargy, drowsiness, loss of appetite and agitation are all symptoms found in 
depression. As has been previously noted, hyponatraemia is rarely diagnosed on clinical 
grounds, particularly in chronic hyponatraemia symptoms are insidious and non-specific 
(Arieff et al., 1976, Kennedy et al., 1978). The detection ofhyponatraemia may therefore 
be serendipitous when routine blood testing is done or the patient presents with another 
illness. Obviously when symptoms are severe e.g. confusion, collapse, dyspnoea, then 
blood testing is more likely to occur. The distribution of the values of the time to 
detection are skewed to the left with modes of 5 and 7 days. Therefore in the majority of 
cases blood testing occurred relatively early and hyponatraemia was detected early. A 
question that has to be answered is how soon after commencing the SSRI does 
hyponatraemia develop? No cases were reported within 12 hours therefore no cases can 
be classified as acute. It seems it can occur within days as a lot of cases were detected 
between days 1 and 7 of treatment. Following on from this, when hyponatraemia occurs 
and assuming it does occur relatively early in all cases, is it then mild or asymptomatic 
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when detected much later or conversely can it occur at any time during treatment? It is 
possible that cases presenting with hyponatraemia after 2 - 3 months of treatment 
developed another condition or took a drug that altered their physiology facilitating the 
occurrence of hyponatraemia. Only prospective research will elucidate these questions. 
1.3 Recovery from hyponatraemia. 
An encouraging finding is that in all cases in both samples in which information was 
given, the serum sodium corrected itself to normal range in 32 days. Of the cases 75% 
corrected in 16 days. This correction occurred after cessation of the SSRI. As a general 
impression from the published case reports, many patients did not receive any specific 
treatment for the hyponatraemia other than cessation of the SSRI and they recovered. 
When treatment was given it was usually fluid restriction and/or a hypertonic saline 
infusion. 
1.4 Severity of hyponatraemia. 
A very clear finding from the Committee on Safety of Medicines and published case 
I 
report samples is that the hyponatraemia, when detected, is moderate to profound. The 
mean serum sodium concentration in both groups was about 118 mmol/1 so half of cases 
had serum sodium concentrations between 98 and 118 mmol/1. As Arieff et al. (1976) 
f 
, 
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pointed out, hyponatraemia of this severity is significantly associated with neurological 
morbidity and mortality. It is not known whether the hyponatraemia associated with 
SSRis is predominantly in the moderate to profound range or whether there is a large 
number of patients receiving SSRis who develop mild, asymptomatic hyponatraemia that 
is never detected. If this were the case then the relevance of mild hyponatraemia would 
have to be determined as it may be insignificant and may not need any action other than 
monitoring serum sodium levels whilst the patient receives SSRis. Alternatively if any 
degree of hyponatraemia heralds the onset of more severe hyponatraemia then detection 
of mild hyponatraemia may be an important finding that can be acted upon to prevent 
severe or profound hyponatraemia. Potentially patients at risk could thus be identified. If 
hyponatraemia does occur early on in treatment then it would be a relatively easy and 
inexpensive procedure to take a blood sample for analysis of serum sodium and stopping 
the SSRI if serum sodium is below the normal range. Unfortunately too many questions 
remain unanswered for such a clinical recommendation to be made. 
1.5 Effect of SSRI on A VP. 
As McAskill & Taylor (1977) hypothesised, since most of these reports ofhyponatraemia 
are of single cases it suggests an idiosyncratic, sporadic occurrence rather than a usual 
phenomenon with SSRis. However contrary to this argument is the possibility that there 
is usually dysregulation of A VP secretion with SSRis but that this is compensated for by 
other physiological processes and it is only in patients in whom these physiological 
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mechanisms are defective that hyponatraemia occurs. This could be tested by 
prospectively measuring A VP levels in patients starting SSRis. Unfortunately measuring 
A VP is an expensive and difficult procedure. In the two cases Girault et al. (1997) 
reported, both subjects had elevated A VP levels in the context of hyponatraemia whilst 
using an SSRI. What is also not clear is the mechanism by which SSRis and 
hyponatraemia are associated. Girault et al. (1997) suggest that elevated serum SSRI 
levels are responsible for increased A VP secretion. With the information that is available 
this is conjecture and there may be a confounding variable that was responsible for both 
raised A VP levels and serum SSRI levels. However, looking at other drugs that directly 
or indirectly affect regulation of A VP secretion, it is more likely that SSRis have a 
similar effect. 
1.6 Sex and hyponatraemia. 
The results concur with the finding of other authors that there is a female preponderance. 
This phenomenon is confirmed by the finding that when the data from the Committee on 
Safety of Medicines was split into two groups, 60 - 69 years and 70 - 98 years, the 
female preponderance increased from 61 % in the younger group to 76 % in the older 
group although this was not statistically associated with hyponatraemia. This in part 
reflects women living longer, therefore representing a greater proportion of the elderly. In 
developed countries 56% of people aged 65 years are female (Grundy, 1992), and this 
figure increases with age so that in the over 80 year old age group women comprise up to 
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70% of that population (Suzman et al., 1992). There is also the increased incidence of 
depression in women. Prevalence rates for depression in the elderly were reported by 
Lindesay et al. (1989) as 11.3 % in women and 8.4 % in men. It can therefore be 
postulated that more women would receive SSRI prescriptions. Sex hormones affect A VP 
secretion in younger women and are probably not a factor in older women (Fraser & 
Arieff, 1997). It would be interesting to know if hormone replacement therapy had an 
effect on A VP secretion. None of the reported cases commented on whether or not 
patients were receiving hormone replacement therapy. 
1. 7 Dose of SSRI and hyponatraemia. 
In the published case report and Committee on Safety of Medicines samples, 6.5% and 
15% of patients respectively had received dosages of SSRI greater than the minimum 
starting dose recommended by the pharmaceutical companies. These dosages are 
fluoxetine 20mg, paroxetine 20mg, sertraline 50mg, fluvoxamine 100mg and citalopram 
20mg. Although not recommende4 by the British National Formulary (British Medical 
Association and Royal Pharmaceutical Society of Great Britain, 1997), it could be argued 
that smaller starting doses should be used in the elderly (Newhouse, 1996, Reynolds, 
1996). Nevertheless the fact that 85-93 .5% cases received a reasonable dose of SSRI 
nowhere near the maximum dose suggests that developing hyponatraemia whilst using 
, 
SSRis is not a dose related adverse reaction. The finding by Girault et al. (1997) of 
elevated SSRI serum levels could be interpreted as there being some abnormality of SSRI 
i 
I 
I 
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metabolism resulting in elevated serum levels. There is the known subgroups of patients 
with a deficiency of certain cytochrome P-450 isoenzymes and they may have elevated 
SSRI plasma levels because these enzymes are necessary for their metabolism (Gram, 
1994, Ereshefsky et al., 1996, Nemerof et al., 1996). This subgroup could be at risk of 
developing hyponatraemia. However if the development of hyponatraemia was related to 
the serum concentratfon of SSRI then it would be expected to find higher rates of 
hyponatraemia in patients receiving larger does of SSRI. This was not apparent in either 
the Committee on Safety of Medicines or published case report samples. It is also 
possible that patients on other drugs that are substrates of the cytochrome P450 enzymes 
that are inhibited by SSRis are now not efficiently metabolised and they may be the 
culprits precipitating hyponatraemia. The elderly are physiologically compromised and 
risk of hyponatraemia may be due the use of multiple drugs and their interaction. 
1.8 Characteristics of hyponatraemia in different age groups and sexes. 
In the re-analysis of the data from the Committee on Safety of Medicines comparing the 
subjects who were 60- 69 years with those who were 70 years and older, the most 
striking finding was that other than the female preponderance being greater in the older 
group, the two groups were remarkably similar. The same held essentially true when the 
sample was divided using the mean age1 as the division point. There were two differences 
in the latter analysis. Firstly the female to male ratio was slightly lower in the older 
group, although the female preponderance was well maintained. Secondly the time to 
1 
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detection of hyponatraemia was significantly shorter in the 79-98 year group. It is 
possible that the older patients are more likely to be frail and more likely to have other 
illnesses and thus more likely to be symptomatic. The overall lack of differences found in 
the different age groups suggests that although the older elderly are at greater risk of 
developing hyponatraemia, the pathophysiology is the same at whatever age it occurs. 
The severity of hyponatraemia is also the same when it occurs. The physiological 
changes making the person vulnerable to developing hyponatraemia occurs at different 
ages in different people (Rowe, 1992). Presumably the same is true for age related 
changes in regulation of A VP secretion. Thus the same process can occur at different 
ages although the frequency is greater with increasing age. 
The data was also analysed looking for differences between the sexes in the whole 
sample. Other than the female to male ratio, no differences were found. There were also 
no differences found when younger females were compared to younger males and older 
females to older males using the 60-69 years vs. 70-98 years and 60-78 years vs. 79-98 
years groups. This also held true when younger same sex subjects were compared to their 
older counterparts in these same groups. This also suggests the same pathophysiology 
occurs in both sexes. 
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1.9 Limitations. 
The major bias in the Committee on Safety of Medicines and published case reports 
samples is that they were comprised of spontaneous reports by clinicians. These reports 
are thus retrospective, of varying quality and completion. The post marketing 
surveillance procedure employed by the Committee on Safety of Medicines relies on 
clinicians identifying adverse reactions to drugs, completing a form and sending it to the 
agency. It is likely many clinicians do not report adverse reactions and many adverse 
reactions are never identified. The function of this type of post marketing surveillance is 
to identify the presence of problems associated with drugs for further research and 
investigation. It is possible only cases of more severe hyponatraemia were reported and 
mild cases may not have been considered worth reporting. Because these were 
spontaneous reports, no estimates of incidence can be inferred from these figures. The 
information given was often incomplete and certainly symptoms patients presented with 
were poorly reported. However when repeated reports are received of an adverse reaction 
associated temporally with a particular drug a causal relationship can be strongly 
suspected. This causal relationship can then strictly only be verified once a 
pathophysiological mechanism is identified and tested. Most accepted adverse drug 
reactions of most drugs are identified only through being regularly reported in association 
with use of the particular agent. The acceptance of hyponatraemia as an adverse reaction 
to SSRis has been by these same standards that are not scientifically rigorous. 
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Case reports were pooled and then analysed because they were all presented in similar 
format so the information gleaned from each report was comparable. Most reports were 
of single cases. A meta-analysis would not have been appropriate. 
2.0 Results of second study. 
Looking at the second study, some questions can be answered. Firstly, none of the six 
subjects showed any alteration in serum and urine sodium concentration and osmolality 
that would suggest dysregulation of A VP secretion. This immediately answers the 
question that hyponatraemia is most likely not a usual phenomenon during the first 2 - 3 
weeks of treatment with an SSRI. This can only be definitively answered by measuring 
AVP directly. The most important contribution to plasma osmolality is made by sodium 
and then in descending order of importance urea, glucose and protein (Hodgkinson, 
1977). In all six subjects their sodium and total protein concentrations were normal. All 
six subjects had at least one raised urea concentration and three had elevated glucose 
concentrations. The abnormal urea and glucose concentrations were compensated for 
because serum osmolality remained within normal limits. 
The ages of the six subjects ranged from 76 years to 83 years, which put them in the age 
group most frequently reported to develop hyponatraemia with SSRI use. None of the 
subjects had a current medical illness commonly associated with SIADH, although two 
had a background history of breast carcinoma and one of these had a background history 
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of tuberculosis. Prior to starting sertraline all six subjects were on drugs known to be 
associated with SIADH. The relevant drugs were non-steroidal anti-inflammatory drugs, , 
diuretics, antipsychotics, lithium and nicotine (smoking). Five subjects were also taking 
drugs that are metabolised by the five Cytochrome P450 isoenzymes relevant to SSRis 
namely non-steroidal anti-inflammatory drugs, tricyclic antidepressants, benzodiazepines 
and antipsychotics. OnJy CYP 2D6 is known to be significantly inhibited by setraline so 
of the drugs taken only thioridazine posed a known risk of interaction by this mechanism. 
The sixth subject was taking digoxin, which is highly protein bound, and may have been 
displaced by Sertraline, which is also highly protein bound. 
All six subjects had a depressive illness which may be associated with altered regulation 
of A VP secretion. So despite these significant factors being present that could have made 
them vulnerable to developing hyponatraemia, none of them did. This could lead to the 
hypothesis that the number of conditions or drugs associated with SIADH present in any 
one patient do not increase the risk of developing SIADH in a cumulative manner, but 
rather that each illness or drug is a risk factor independent of each other. Unfortunately 
this assumption cannot be tested in such a small sample. However if this hypothesis were 
true then it would not be helpful to identify illnesses and drugs associated with SIADH as 
a way of predicting if a patient would develop hyponatraemia when commencing an 
SSRI, although obviously these factor, increase the overall likelihood of the patient 
developing hyponatraemia. 
1 
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2.1 A VP secretion in presence of SSRis. 
It is interesting to note the serum osmolality in all six cases was above the threshold for 
A VP secretion (280 mmol/1), serum sodium concentration was normal and the urine was 
concentrated. From this it can be inferred that AVP is being secreted appropriately and 
water balance is maintained. These subjects are probably slightly in negative water 
balance suggested by serum osmolality in the higher range of normal and concentrated 
urine and this is probably because of the blunted thirst response associated with aging. 
An interesting intervention would be to give them a fluid challenge and see if water 
balance is maintained or if they develop hypo-osmolar hyponatraemia because of 
persistent AVP secretion i.e. are they being 'saved' by their blunted thirst response? 
2.2 Limitations 
A major shortcoming of this part of the study is that serum A VP levels were not directly 
measured. The sample size is small making generalisations invalid. There was also no 
control group, but this would have been difficult to set up as so many variables would 
have had to have been matched e.g. age, sex, illnesses, drugs etc. Taking the blood 
sample between two to three weeks may have missed any alterations in A VP function 
immediately on starting sertraline whic~ may subsequently have been corrected. If 
hyponatraemia had occurred the only evidence suggesting a causal relationship with 
sertraline would have been time, nevertheless this would not have excluded the 
l 
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hyponatraemia being due to another drug, illness or an idiopathic reaction. This 
distinction would be difficult to make even if A VP levels were measured. From the point 
of view of confounding variables the sample was typical of patients presenting to 
psychogeriatric services. 
3.0 Null Hypothesis 
The data from the published case reports and the Committee on Safety of Medicines 
suggest the null hypothesis may be false however the results from the six subjects taking 
sertraline upheld the null hypothesis. It is reasonable to infer the null hypothesis is 
sometimes false. 
4.0 Conclusions 
In summary there is an association between SSRis and hyponatraemia. It is probably is a 
sporadic, idiosyncratic phenomenon that is not dose related. The exact mechanism is not 
known although there have been two cases reported with elevated A VP levels and in 
reported cases in the literature urine and blood pictures have been compatible with 
SIADH. The elderly are at greater risk and the older elderly, over 70 years, are at greatest 
risk. Females comprise the majority of the cases but this has more to do with factors such 
as longevity and incidence of depression than women being at greater risk. The 
,. 
- 71 -
physiological characteristics of the hyponatraemia is similar at whatever age it occurs and 
in both sexes. 
It is very likely that the hyponatraemia occurs within the first two weeks of treatment so 
clinicians should look for it if patients present with non-specific symptoms, even if these 
symptoms could be explained by other conditions present, including depression. Most 
cases of hyponatraemia resolve within about two weeks of stopping the SSRI. The cases 
of hyponatraemia reported thus far were predominantly moderate to profound so it should 
be taken seriously as hyponatraemia of this severity is associated with considerable 
morbidity and mortality. 
There are further questions that still need clarification. It is not known whether 
inappropriate secretion of A VP is sufficient to cause hyponatraemia or if hyponatraemia 
only occurs when there is another defect in physiological mechanisms maintaining water 
balance, such as those occurring in the elderly. Polypharmacy and drug interactions 
particularly involving the cytochrome P450 enzymes may also play a role. It is also 
unclear if the hyponatraemia is generally moderate to profound or if there is a large group 
of patients developing mild hyponatraemia that is never detected or reported. It would be 
helpful to be able to predict who would be at risk of developing hyponatraemia prior to 
starting the SSRI. Thus far the only clear predictor is age. The presence of other illnesses 
or drugs associated with SIADH or physiological changes affecting control of water 
balance need to be further investigated to establish their predictive value. 
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lbis study of six prospective cases merely gives an indication of the effects of an SSRI 
and clinical recommendations cannot be made from such a small sample. More 
prospective studies over longer periods of time are needed directly measuring A VP in 
people using SSRis to establish if hyponatraemia is related to serum SSRI levels and 
inappropriate secretion of A VP and how this relates to compromised physiology and drug 
interactions. 
5.0 Clinical Recommendations 
From this investigation it can be recommended to clinicians that it is advisable to test 
serum sodium concentration within the first two weeks of starting an SSRI in the elderly. 
Hyponatraemia should be considered in patients who present with non-specific symptoms 
such as confusion, weakness, lethargy ,drowsiness. If hyponatraemia occurs the SSRI 
should be stopped and serum sodium concentration monitored until it returns to normal, 
usually within 2-3 weeks. If serum sodium concentration does not begin improving 
within in the first few days of stopping the SSRI other causes of hyponatraemia must be 
considered. The patient could be rechallenged with a different SSRI whilst serum sodium 
concentration is carefully monitored. 
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